On July 1, 2014, Pozen Inc (NASDAQ:POZN) announced it had resubmitted the New Drug Application (NDA) for PA81/40 and PA325/40 to the U.S. FDA. Pozen noted that the FDA is expected to notify the company within 14 days of receipt of the NDA whether or not the submission will be accepted, and if accepted, what the new PDUFA date will be. More specifically, we will find out in two weeks if the FDA will take two months or six months to review the application.
We remind investors that on April 25, 2014, Pozen announced receipt of a complete response letter (NYSE:CRL) for PA8140/PA32540. In the CRL, the FDA noted that, "During an inspection of the...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|